Night Sweats
9
1
1
7
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
0.0%
0 terminated out of 9 trials
100.0%
+13.5% vs benchmark
22%
2 trials in Phase 3/4
57%
4 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (9)
Herbal Dietary Supplementation on Vasomotor Symptoms in Menopausal Women
JDS-HF3.0 Supplementation on Menopause Related Quality of Life Outcomes in Postmenopausal Women
Obinutuzumab and Lenalidomide in Treating Patients With Previously Untreated Stage II-IV Grade 1-3a Follicular Lymphoma
Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia
Progesterone for Perimenopausal Night Sweats
Ex Vivo-activated Autologous Lymph Node Lymphocytes in Treating Patients With Chronic Lymphocytic Leukemia
Lenalidomide and Ofatumumab in Treating Participants With Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Applied Relaxation (AR) Technique Versus Its Modified Version for Treating Menopausal Symptoms
Comparison of Hormonal Therapy: Mediating Hot Flashes Tapering Regimens for Mediating Hot Flashes